A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) metered dose inhaler (MDI) Hydrofluoroolefin (HFO) with a spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) with a spacer (Treatment A), as well as BGF MDI HFO without a spacer (Treatment C)

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.